早期与晚期恶性卵巢生殖细胞肿瘤保守治疗后的生育结局
多中心意大利卵巢癌试验(MITO)中心对1983至2019年间诊断的114例生殖年龄恶性卵巢生殖细胞肿瘤(MOGCT)患者进行问卷随访,其中109例应答、5例死亡。57.9%接受化疗,BEP后月经恢复中位时间5.6个月,仅1例早发性卵巢功能不全;38例尝试妊娠,29例(76.3%)成功,共44次受孕。
要点
- MOGCT保守治疗后仅1例早发性卵巢功能不全,BEP化疗后月经恢复中位时间5.6个月。
- 38例尝试妊娠者中29例(76.3%)获得妊娠,共44次受孕。
- 接受化疗者中40.9%妊娠,未接受化疗者中22.9%妊娠(p=0.048)。
核心结论
- MOGCT影响育龄女性,保留生育功能是重要治疗议题;结果与现有证据一致,证实MOGCT辅助化疗不影响生殖功能与生育力。
研究设计与样本
- 多中心意大利卵巢癌试验(MITO)中心对164例MOGCT生存者发放问卷,收集妇科症状、生育结局及生育治疗信息;死亡患者数据取自MITO-9数据库;纳入1983至2019年间诊断的114例生殖年龄患者,109例应答问卷、5例死亡患者纳入分析,中位年龄24.9岁。
主要发现
- 分期为I期78.1%、II期4.4%、III期14.9%、IV期2.6%。
- 57.9%接受化疗,平均周期数4.1。
- BEP后月经恢复中位时间5.6个月,仅报告1例早发性卵巢功能不全。
- 114例中38例(33.3%)尝试妊娠,29/38(76.3%)获得妊娠,共44次受孕。
- 尝试妊娠者中,接受化疗者40.9%获得活产,未接受化疗者22.9%获得活产(p=0.048);妊娠意愿是治疗后尝试妊娠女性中与活产相关的唯一预测因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Malignant ovarian germ cell tumors usually occur in young women. The standard of care is fertility sparing surgery and comprehensive surgical staging followed by adjuvant chemotherapy with BEP (bleomycin, etoposide, cisplatin) if needed. The aim of this study was to analyze the reproductive outcomes after conservative treatment in patients diagnosed, treated and followed up in MITO (Multicenter Italian Trials in Ovarian Cancer) centers. METHODS: A questionnaire concerning gynecological symptoms, reproductive outcomes and fertility treatment was administered to 164 MOGCTs survivors. Data regarding patients deceased were collected from MITO-9 database. There were 114 patients diagnosed at reproductive age between 1983 and 2019 included. RESULTS: 109 patients answered the questionnaire and 5 patients decesased were included (median age 24.9 years). 78.1% were stage I,4.4% stage II, 14.9% stage III and 2.6% stage IV. 57.9% received chemotherapy, the mean number of cycles was 4.1. Median time to menstrual recovery after BEP was of 5.6 months range, only 1 case of premature ovarian failure was reported. Among the 114 patients 38 (33.3%) attempted to become pregnant, 29/38 (76.3%) got pregnant with a total of 44 conceptions. 40.9% received chemotherapy and 22.9% did not (p 0.048). Pregnancy desire was the only predictive factor associated with live births among women who attempted pregnancy after treatment. CONCLUSIONS: As MOGCTs affect women of child-bearing age, fertility preservation represents a major treatment issue. Our results are consistent with the available evidence, confirming that adjuvant chemotherapy for MOGCT does not impact the reproductive function and fertility.
引用
- Vasta FM, Cormio G, Cassani C, et al. Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs. Gynecol Oncol. 2023. PMID: 38104526. doi:10.1016/j.ygyno.2023.11.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。